Patent EP4039703A1: Chimeric Antigen Receptor and Anti C-Met Antibody

The European Patent Office has published patent application EP4039703A1 concerning a Chimeric Antigen Receptor comprising an anti-C-Met antibody or antigen binding fragment thereof. The patent was published on March 11, 2026, with Helixmith Co., Ltd. listed as the applicant.

EPO Patent EP4019536A1: Immunocytokine Preparation and Uses

The European Patent Office has published patent application EP4019536A1 concerning an immunocytokine preparation and its uses. The patent was published on March 11, 2026, with YiChen Therapeutics Limited listed as the applicant.

EPO Patent Publication EP4048786A1 on Chimeric Polypeptides

The European Patent Office has published patent application EP4048786A1 concerning chimeric polypeptides and their uses. The publication date is March 11, 2026, and the applicants include Genethon, Universite d'Evry Val d'Essonne, INSERM, and SORBONNE UNIVERSITE.

EPO Patent EP4074833A1: Restricted Immunoglobulin Heavy Chain Mice

The European Patent Office has published patent application EP4074833A1 concerning restricted immunoglobulin heavy chain mice, with Regeneron Pharmaceuticals, Inc. listed as the applicant. This publication is part of the EPO's regular bulletin for peptides.

EPO Patent EP4032544A2: Novel T Cell Receptors and Immune Therapy

The European Patent Office has published patent application EP4032544A2 concerning novel T cell receptors and their use in immune therapy. The patent is assigned to Immatics Biotechnologies GmbH and lists several inventors. The publication date is March 11, 2026.

Improved Peptide Pharmaceuticals Patent Application EP4047023A1

The European Patent Office has published patent application EP4047023A1 concerning improved peptide pharmaceuticals, filed by Eumederis Pharmaceuticals, Inc. The publication date is March 11, 2026, and it covers various peptide classifications and applications.

EPO Patent Publication: Peptide for Treating Inflammation and Wounds

The European Patent Office has published patent application EP4059946A1 for a peptide composition intended for treating inflammation and wounds. The publication lists Nibec Co., Ltd. as the applicant and details the inventors and IPC classifications related to the peptide.

EPO Patent EP3722318A1: Multispecific Antigen-Binding Molecules

The European Patent Office has published patent application EP3722318A1 concerning multispecific antigen-binding molecules, filed by Regeneron Pharmaceuticals, Inc. The publication date is March 11, 2026, and it covers various classifications related to antibodies and their uses.

FGFR-Targeted Antagonistic Short Peptide Patent Application

The European Patent Office has published patent application EP2021115258A1 concerning an FGFR-targeted antagonistic short peptide. The application was published on March 11, 2026, with Wenzhou Medical University listed as the applicant.

EPO Patent Application EP3981790A1 - CD73 Binding Molecule

The European Patent Office has published patent application EP3981790A1 concerning a CD73 binding molecule and its use, filed by Jacobio Pharmaceuticals Co., Ltd. This publication provides notice of the patent application's details, including inventors and classifications.